表紙
市場調査レポート

主要先進国における2020年までの大腸がん治療薬市場:高額薬剤の取り込み増大でジェネリックの影響を相殺

Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics

発行 GBI Research 商品コード 326287
出版日 ページ情報 英文 104 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
主要先進国における2020年までの大腸がん治療薬市場:高額薬剤の取り込み増大でジェネリックの影響を相殺 Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics
出版日: 2015年01月31日 ページ情報: 英文 104 Pages
概要

主要先進国における大腸がん治療薬市場は、2020年には94億米ドル規模まで拡大し、CAGRで1.8%の成長が予測されています。

当レポートでは、主要先進国における大腸がん治療薬市場について調査分析し、市場の概要、上市製品、パイプライン製品、市場予測、取引と戦略的統合などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

  • 大腸がん
  • 症状
  • 疫学
  • 病態生理
  • 診断
  • 予後と病期
  • 治療の選択肢

第3章 上市製品

  • 主な上市製品
  • 上市製品のヒートマップ

第4章 パイプライン分析

  • パイプライン全体
  • パイプライン分析:分子タイプ別
  • パイプライン分析:作用機序別
  • 臨床試験
  • 失敗率
  • 臨床試験の規模
  • 期間
  • パイプラインにおける有望薬の候補
    • Lonsurf (TAS-102KKKKK (tipiracil + trifluridine))
    • Cyramza - ramucirumab
    • TS-1/Teysuno (tegafur + gimeracil + oteracil)
    • CPP-1X (eflornithine hydrochloride) + sulindac
    • MelCancerVac
    • Xilonix
    • Nintedanib

第5章 市場予測

  • 世界市場
  • 北米
  • 欧州主要5ヶ国
  • 日本
  • 促進要因と障壁

第6章 取引と戦略的統合

  • ライセンス取引
  • 共同開発取引

第7章 付録

図表

目次
Product Code: GBIHC352MR

Executive Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics", which provides in-depth analysis of the Colorectal Cancer (CRC) therapeutics market in the eight major geographies of the US, Canada, the UK, France, Germany, Spain, Italy and Japan. The report provides an estimation of the market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth pipeline analysis, and deal analysis.

The CRC therapeutics market in the eight major markets is expected to grow at a Compound Annual Growth Rate (CAGR) of 1.8% to $9.4 billion by 2020. The US had the largest market share in 2013, equivalent to a global share of 44.1%, followed by Japan and Germany with 14.7% and 11.9% respectively. Spain had the lowest market share of the leading eight at 4.1%. All markets covered in the report are expected to witness a slower growth rate than Japan, which will grow at a CAGR of 5%. However, this moderate growth will be stymied by the expected uptake of lower-priced biosimilar versions of bevacizumab and cetuximab due to the expiration of the patents of Avastin and Erbitux in the latter half of the forecast period. Also expected is the launch of generic versions of capecitabine, which will also affect the market. However, this will be offset by the launch of premium-priced emerging therapies. Stivarga is expected to be one of the biggest drivers of growth in the CRC market, primarily due to its expected line extension in the first-line metastatic setting as a maintenance treatment for patients with resected liver metastases. The launch of Lonsurf (TAS-102), approved in Japan in 2014, in the third- and fourth-line settings will further increase the pharmacological treatment rates in these lines, which will give patients a more tolerable alternative to Stivarga. The moderate uptake of other late-stage pipeline products, panitumumab and Xilonix, following their expected approval, is expected to drive additional growth within this market.

The CRC pipeline is highly robust, with potential drug candidates across various Phases of clinical development. With nearly 400 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or second-line therapies. The current investigational pipeline candidates include new combination therapies and targeted therapies, as well as promising immunotherapies and chemotherapy drug candidates. As well as these active progressing pipeline molecules, the pipeline also includes nearly 180 molecules that are either inactive or discontinued.

Scope

The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the eight major markets: the US, the UK, France, Germany, Spain, Italy, Japan and Canada. It includes -

  • A brief introduction to CRC, including the disease's pathogenesis, etiology, diagnosis and treatment algorithms
  • In-depth analysis of currently marketed drugs for CRC, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy
  • A comprehensive review of the pipeline for CRC, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
  • Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
  • Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
  • Discussion of the drivers of and barriers to market growth
  • In-depth analysis of all licensing and co-development deals that have occurred in the CRC market since 2006

Reasons to buy

  • The report will enhance your decision-making capability by allowing you to -
  • Understand the CRC pipeline and the factors that indicate that it is becoming more innovative
  • Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be
  • Follow the trends in CRC clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates
  • Observe the potential growth patterns expected for the CRC market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the CRC market
  • Accelerate and strengthen your market position by identifying key companies for strategic partnerships

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Colorectal Cancer
  • 2.2. Symptoms
  • 2.3. Epidemiology
  • 2.4. Pathophysiology
    • 2.4.1. Histology
    • 2.4.2. Genetic Basis
    • 2.4.3. Etiology of Colorectal Cancer
  • 2.5. Diagnosis
    • 2.5.1. Digital Rectal Examination
    • 2.5.2. Fecal Occult Blood Test
    • 2.5.3. Flexible Sigmoidoscopy
    • 2.5.4. Colonoscopy
    • 2.5.5. Virtual Colonoscopy
    • 2.5.6. Double Contrast Barium Enema
  • 2.6. Prognosis and Disease Staging
  • 2.7. Treatment Options
    • 2.7.1. Surgery and Radiation Therapy
    • 2.7.2. Chemotherapy
    • 2.7.3. Targeted Therapies
    • 2.7.4. Resistance to Pharmacological Therapies
    • 2.7.5. Treatment Guidelines

3. Marketed Products

  • 3.1. Key Marketed Products
    • 3.1.1. Immunotherapies
    • 3.1.2. Targeted Therapies
    • 3.1.3. Hyperthermic Intraperitoneal Chemotherapy
  • 3.2. Heat Map for Marketed Products

4. Pipeline Analysis

  • 4.1. Overall Pipeline
  • 4.2. Pipeline Analysis by Molecule Type
  • 4.3. Pipeline Analysis by Mechanism of Action
  • 4.4. Clinical Trials
  • 4.5. Failure Rate
  • 4.6. Clinical Trial Size
  • 4.7. Duration
  • 4.8. Promising Drug Candidates in Pipeline
    • 4.8.1. Lonsurf (TAS-102KKKKK (tipiracil + trifluridine)) - Taiho Pharmaceutical
    • 4.8.2. Cyramza - ramucirumab - Eli Lilly and Company
    • 4.8.3. TS-1/Teysuno (tegafur + gimeracil + oteracil) - Taiho Pharmaceutical
    • 4.8.4. CPP-1X (eflornithine hydrochloride) + sulindac - Cancer Prevention Pharmaceuticals
    • 4.8.5. MelCancerVac - DanDrit Biotech
    • 4.8.6. Xilonix - XBiotech
    • 4.8.7. Nintedanib - Boehringer Ingelheim

5. Market Forecast to 2020

  • 5.1. Global Market
    • 5.1.1. Treatment Use Patterns
    • 5.1.2. Market Size
  • 5.2. North America
    • 5.2.1. Treatment Use Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Size
  • 5.3. Top Five European Markets
    • 5.3.1. Treatment Use Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. Japan
    • 5.4.1. Treatment Use Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Drivers and Barriers for the Colorectal Cancer Therapeutics in Major Developed Markets to 2020
    • 5.5.1. Drivers
    • 5.5.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Licensing Agreements
    • 6.1.1. Major Licensing Deals
  • 6.2. Co-development Agreements
    • 6.2.1. Major Co-development Agreements

7. Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-Filed
    • 7.1.4. Phase I
    • 7.1.5. Phase II
    • 7.1.6. Phase III
  • 7.2. Market Forecasts to 2020
    • 7.2.1. Global
    • 7.2.2. US
    • 7.2.3. Canada
    • 7.2.4. UK
    • 7.2.5. France
    • 7.2.6. Germany
    • 7.2.7. Italy
    • 7.2.8. Spain
    • 7.2.9. Japan
  • 7.3. Market Definitions
  • 7.4. Abbreviations
  • 7.5. References
  • 7.6. References for Heat Map
  • 7.7. Research Methodology
    • 7.7.1. Coverage
    • 7.7.2. Secondary Research
    • 7.7.3. Primary Research
    • 7.7.4. Therapeutic Landscape
    • 7.7.5. Geographical Landscape
    • 7.7.6. Pipeline Analysis
  • 7.8. Expert Panel Validation
  • 7.9. Contact Us
  • 7.10. Disclaimer

List of Tables

  • Table 1 Colorectal Cancer Therapeutics, Global, TNM Staging, 2013
  • Table 2 Surgical Options for Colorectal Cancer
  • Table 3 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2014
  • Table 4 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2014
  • Table 5 Colorectal Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed), 2014
  • Table 6 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2014
  • Table 7 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2014
  • Table 8 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2014
  • Table 9: Colorectal Cancer Therapeutics, Global, Forecast Data, 2013-2020
  • Table 10: Colorectal Cancer Therapeutics, US, Forecast Data, 2013-2020
  • Table 11: Colorectal Cancer Therapeutics, Canada, Forecast Data, 2013-2020
  • Table 12: Colorectal Cancer Therapeutics, UK, Forecast Data, 2013-2020
  • Table 13: Colorectal Cancer Therapeutics, France, Forecast Data, 2013-2020
  • Table 14: Colorectal Cancer Therapeutics, Germany, Forecast Data, 2013-2020
  • Table 15: Colorectal Cancer Therapeutics, Italy, Forecast Data, 2013-2020
  • Table 16: Colorectal Cancer Therapeutics, Spain, Forecast Data, 2013-2020
  • Table 17: Colorectal Cancer Therapeutics, Japan, Forecast Data, 2013-2020
  • Table 18: Colorectal Cancer Market, References for Heat Map

List of Figures

  • Figure 1: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology Treatment Guidelines (Colorectal Cancer at Stage I to III)
  • Figure 2: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology Treatment Guidelines (Colorectal Cancer at Stage IV)
  • Figure 3: Colorectal Cancer Therapeutics, Global, Heat Map (Marketed Products)
  • Figure 4: Colorectal Cancer Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2014
  • Figure 5: Colorectal Cancer Therapeutics, Global, Pipeline by Molecule Type and Stage of Development, 2014
  • Figure 6: Colorectal Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of Development, 2014
  • Figure 7: Colorectal Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2014
  • Figure 8: Colorectal Cancer Therapeutics, Global, Clinical Trial Size, 2014
  • Figure 9: Colorectal Cancer Therapeutics, Global, Clinical Trial Duration (months), 2014
  • Figure 10: Colorectal Cancer Therapeutics, Global, Treatment Use Patterns ('000) and Market Size ($bn), 2013-2020
  • Figure 11: Colorectal Cancer Therapeutics, US and Canada, Treatment Use Patterns ('000), 2013-2020
  • Figure 12: Colorectal Cancer Therapeutics, US and Canada, Annual Cost of Therapy ($), 2013-2020
  • Figure 13: Colorectal Cancer Therapeutics, US and Canada, Market Size ($m), 2013-2020
  • Figure 14: Colorectal Cancer Therapeutics, Top Five European Markets, Treatment Use Patterns ('000), 2013-2020
  • Figure 15: Colorectal Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2013-2020
  • Figure 16: Colorectal Cancer Therapeutics, Top Five European Markets, Market Size ($m), 2013-2020
  • Figure 17: Colorectal Cancer Therapeutics, Japan, Treatment Use Pattern, 2013-2020
  • Figure 18: Colorectal Cancer Therapeutics, Japan, Annual Cost of Therapy, 2013-2020
  • Figure 19: Colorectal Cancer Therapeutics, Japan, Market Size ($m), 2013-2020
  • Figure 20: Colorectal Cancer Therapeutics, Global, Licensing Deals by Geography, 2006-2014
  • Figure 21: Colorectal Cancer Therapeutics, Global, Licensing Deals by Phase, Value, Mechanism of Action, 2006-2014
  • Figure 22: Colorectal Cancer Market, Global, Co-development Deals by Geography and by Value, 2006-2014
  • Figure 23: GBI Research Market Forecasting Model
Back to Top